NEW YORK, May 10 - InforMax has licensed its GenoMax bioinformatics software to Abgenix, the company said Thursday.
The licensing agreement, which occurred during the first quarter, comprises one of 32 sales to pharmaceutical, biotechnology, and academic customers, according to InforMax CEO Alex Titomirov.
GenoMax integrates UNIX, Oracle, and Java technologies for analysis of mass quantities of genomic data and target selection. It works in tandem with Vector NTI suite, InforMax's desktop product for wet lab work.
"The GenoMax bioinformatics system will help us to organize and manage the genomics data for our antibody-based therapeutics,” said Keith Joho, director of bioinformatics for Abgenix, in a statement. “We expect GenoMax to help expedite our analysis of targets and antibodies in our large-scale product discovery efforts."
The companies did not disclose the financial details of the agreement.
Other InforMax customers for GenoMax include the Whitehead Institute/MIT Center for Genome Research, PPD Discovery, DuPont, Pioneer Hi-Bred International, Genzyme, The University of Tokyo, and AxCell Biosciences, in collaboration with which the company has added a database of human protein interactions to the product. InforMax, of Rockville, Md., claims to have over 22,000 individual users of its software worldwide at 1,300 research organizations.